COVID-19 brings divisions on hydroxychloroquine, reopening

Fiercepharma | May 19, 2020

COVID-19 brings divisions on hydroxychloroquine, reopening
Welcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. As the pandemic plays out, political divisions have unfolded around hydroxychloroquine and reopening economies, for starters. At center stage last week was a House hearing over ousted Biomedical Advanced Research and Development Authority (BARDA) Director Rick Bright’s whistleblower complaint. While the hearing spanned numerous subjects relating to the U.S.' COVID-19 response, lawmakers and Bright spent considerable time discussing hydroxychloroquine. President Donald Trump backed the drug as a "game changer," but so far, hydroxychloroquine hasn't succeeded in any any large controlled studies.

Spotlight

Dr. Shekhar Saxena, Director, Department of Mental Health and Substance Abuse, World Health Organization, sits down with Mario Ottiglio, IFPMA, to discuss latest trends on mental & neurological disorders.

Related News

Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging

Telix Pharmaceuticals Limited | September 07, 2020

Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announced it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform. Under the terms of the agreement, the parties will leverage Telix’s extensive clinical data for imaging prostate-specific membrane antigen (PSMA) with positron emission tomography (PET) to potentially develop new image-guided treatment planning functions, automated analysis and artificial intelligence capabilities within Varian’s radiation treatment planning technology platforms. The goal of the collaboration is to ensure that the latest standard of care in prostate imaging is able to be an integral part of radiation treatment planning.

Read More

RESEARCH

Gilead gets WHO cold shoulder for remdesivir in COVID-19, launches speedy defense

Gilead | November 21, 2020

Gilead Sciences’ Veklury, better known as remdesivir, is so far the only COVID-19 therapy officially approved by the FDA, but the World Health Organization has some other ideas about the drug’s worth. At clear odds with the FDA’s approval, the WHO has for now recommended against the use of remdesivir in any hospitalized patients—regardless of disease severity—after an expert panel said it had found no evidence that remdesivir has any meaningful effect on saving lives and other important outcomes for patients, the international body said Thursday. A “disappointed” Gilead immediately fought back. It pointed to remdesivir’s inclusion in several other organizations’ guidelines based on data from a phase 3 trial by the National Institute of Allergy and Infectious Diseases (NIAID), which showed the drug’s use could lead to faster recovery.

Read More

PHARMA TECH

BenchSci Named a Deloitte Technology Fast 50™ Company as Impact on Drug Discovery Grows

BenchSci, Deloitte Technology Fast 50™ | November 23, 2021

BenchSci, an emerging global leader in machine learning applications for novel medicine development, announced it ranks 19th among the country’s fastest-growing technology companies in the Deloitte Technology Fast 50™. The program awards companies for their rapid revenue growth, entrepreneurial spirit, and bold innovation, and consists of public and private companies in the tech sector which have transformed the industry. “This recognition is a confirmation of our groundbreaking work to bring novel medicine to patients faster. Our machine learning technology decodes and organizes the world’s most comprehensive biomedical dataset like a Ph.D. scientist. As a result, we eliminate experiments that delay progress and drain research budgets in the world’s largest pharmaceutical companies. This award reflects the value we’re bringing not only to our customers’ research productivity but to all of us who benefit from healthcare innovation.” Liran Belenzon, CEO, BenchSci To qualify for the Tech Fast 50™, companies must have been in business for at least four years, have revenues of at least $5 million, be headquartered in Canada, own proprietary technology, conduct research and development activities in Canada, and invest a minimum of five percent of gross revenues in Research and Development. Founded in 2015, BenchSci has rapidly grown its customer base since launching commercially in 2017. In addition to powering research in over 4,300 academic labs, BenchSci is an indispensable tool for preclinical R&D in 15 of the top 20 global pharmaceutical companies. A remote-first company with headquarters in Toronto, BenchSci is a leader in biomedical machine learning and continuously invests in researching and developing AI-powered tools to help scientists run more successful experiments. “I am thankful for the innovation and commitment of our team members that enable scientists to accelerate drug discovery,” continues Belenzon. “We are honored with the trust our customers place in us as we build the next generation of products that will continue to transform R&D.” About the Deloitte Technology Fast 50™ program The Deloitte Technology Fast 50 program is Canada’s pre-eminent technology awards program. Celebrating business growth, innovation and entrepreneurship, the program features distinct categories, including the Technology Fast 50 ranking, Enterprise Fast 15, Clean Technology, and Companies-to-Watch. The program also recognizes companies within the North American Technology Fast 500 ranking, identifying technology companies in the United States and Canada. The 2021 program sponsors include Deloitte, RBC, EDC, Miller Thomson, Clarity Recruitment, and Lafond. About BenchSci BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. We’re achieving it by empowering scientists with the world’s most advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, our platform accelerates science at 15 top-20 pharmaceutical companies and over 4,300 leading research centers worldwide. We’re a Deloitte Tech Fast 50 and CIX Top 10 Growth company, certified Great Place to Work®, and top-ranked company on Glassdoor.

Read More

Spotlight

Dr. Shekhar Saxena, Director, Department of Mental Health and Substance Abuse, World Health Organization, sits down with Mario Ottiglio, IFPMA, to discuss latest trends on mental & neurological disorders.